VOLUNTIS news, videos and press releases
For more news please use our advanced search feature.
VOLUNTIS - More news...
VOLUNTIS - More news...
- Voluntis announces the success of the Tender Offer initiated by the company Aptar allowing the implementation of mandatory squeeze-out
- Voluntis announces its results for the first half of 2021
- Aptar Announces the Completion of the Acquisition of a Majority Stake in Voluntis
- Voluntis announces the completion of the acquisition by Aptar of a majority stake in Voluntis at a price of EUR 8.70 per share
- Aptar Announces the Signature of a Share Purchase Agreement Regarding the Acquisition of a Majority Stake in Voluntis at a Price of €8.70 Per Share
- Voluntis announces the execution of a Share Purchase Agreement between its reference shareholders and Aptar regarding the acquisition of a majority stake in Voluntis at a price of EUR 8.70 per share
- Exclusive Negotiations Regarding a Potential Acquisition of Voluntis by Aptar to Expand in Digital Therapeutics
- Aptar Announces Exclusive Negotiations Regarding a Potential Acquisition of Voluntis to Expand in Digital Therapeutics
- Voluntis receives FDA 510(k) clearance for a new version of Insulia supporting an expanded range of basal insulins
- Voluntis receives CE Mark for new version of Oleena with expanded clinical intelligence
- Voluntis, a pioneer-turned-leader in digital therapeutics, sets out its ambitions for profitable growth
- Voluntis and Eisai to Collaborate on Digital Therapeutics for Oncology Patients
- Voluntis: 2020 Annual Results in Line With the Roadmap, Demonstrating the Success of the New Strategy, and Confirmed Confidence in the Plan
- Broward Health and Voluntis Launch a New Clinical Evaluation Program on Digital Therapeutics for Metastatic Breast Cancer
- Voluntis Announces the Organization of Meetings With Institutional Investors Accompanied by Brokerage Firm Gilbert Dupont
- Voluntis Strengthens Its Global Customer Support Services in Collaboration With Zendesk
- Publication of a New Study on Voluntis by Brokerage Firm Bryan, Garnier & Co
- Voluntis: Initiation of Voluntis Stock Coverage by the Brokerage Firm Gilbert Dupont
- Transfer of Voluntis Shares to the Euronext Growth Paris Market Effective on February 17, 2021
- Voluntis Announces Issuance of European Patent for Drug Dosing Support With Its Theraxium Digital Therapeutic Platform
- Transfer of Voluntis Shares to the Euronext Growth Paris Market Effective on February 17, 2021
- Voluntis: Commercial Successes and Financial Operations Put Voluntis on Track to Deliver on Its Strategic Roadmap in 2021 and Beyond
- Voluntis Obtains €3 Million of Additional Non-Dilutive Loans and Optimizes Its Existing Financing
- Voluntis Shareholders’ Approval of the Securities Listing Transfer Project to the Euronext Growth Market in Paris
- Voluntis Successfully Completes a Capital Increase of €5.9 Million and Finalizes the Financing of Its Strategic Roadmap
- Voluntis: Launch of a New R&D Program to Extend the Theraxium Platform Supported by a Loan from Bpifrance
- Voluntis Receives CE Mark for Oleena, Key Milestone to the Future Commercialization of Its Digital Therapeutics for Oncology
- Voluntis Extends Its Digital Therapeutics Cloud Infrastructure Worldwide with Microsoft
- Voluntis and Redox Enter Into New Partnership to Enable Interoperability of Digital Therapeutics With Electronic Health Records
- Voluntis: Project to Transfer the Listing of Securities to the Euronext Growth Market in Paris
